ACP-204

Phase 3Recruiting

0 views this week 0 watching⚡ Active🧠Featured in Neuroscience Pipeline Watch

Interest: 44/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Alzheimer's Disease Psychosis

Conditions

Alzheimer's Disease Psychosis

Trial Timeline

Apr 23, 2024 → May 1, 2029

NCT ID

NCT06194799

About ACP-204

ACP-204 is a phase 3 stage product being developed by Acadia Pharmaceuticals for Alzheimer's Disease Psychosis. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06194799. Target conditions include Alzheimer's Disease Psychosis.

What happened to similar drugs?

20 of 20 similar drugs in Alzheimer's Disease Psychosis were approved

Approved (20) Terminated (2) Active (0)

✅Alfoatirin® Tab. + Aripezil® Tab. + Aripezil® Tab.YuhanApproved

✅DonepezilEisaiApproved

✅DONEPEZIL HYDROCHLORIDEEisaiApproved

✅Donepezil HCLEisaiApproved

✅Donepezil HClEisaiApproved

✅Donepezil HydrochlorideEisaiApproved

✅AriceptEisaiApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (2)

NCT ID	Phase	Status	Start	Completion	Indication
NCT07095465	Phase 3	Recruiting	Nov 14, 2025	Mar 1, 2029	Lewy Body Dementia Psychosis
NCT06194799	Phase 3	Recruiting	Apr 23, 2024	May 1, 2029	Alzheimer's Disease Psychosis

Competing Products

20 competing products in Alzheimer's Disease Psychosis

See all competitors

Product	Company	Stage	Hype Score
LY450139 + Placebo	Eli Lilly	Phase 3	40
Solanezumab + Placebo	Eli Lilly	Phase 3	32
LY450139 dihydrate + placebo	Eli Lilly	Phase 2	35
GSK4527226	Alector	Phase 2	29
GSK4527226	Alector	Phase 2	32
AL002	Alector	Phase 2	17
Solanezumab + Placebo	Eli Lilly	Phase 3	32
simufilam	Cassava Sciences	Phase 2	17
Remternetug + Placebo	Eli Lilly	Phase 3	44
solanezumab	Eli Lilly	Phase 2	35
LY2886721 + Placebo	Eli Lilly	Phase 1	29
Gantenerumab + Gantenerumab + Gantenerumab + Placebo	Chugai Pharmaceutical	Phase 1	29
Alfoatirin® Tab. + Aripezil® Tab. + Aripezil® Tab.	Yuhan	Approved	39
FK962	Astellas Pharma	Phase 2	27
ASP0777 + Placebo	Astellas Pharma	Phase 1	29
Elenbecestat + Placebo	Eisai	Phase 3	32
Donepezil	Eisai	Approved	43
Aricept (donepezil SR 23 mg) + Aricept (donepezil IR 10 mg)	Eisai	Phase 3	40
Donepezil hydrochloride	Eisai	Phase 3	40
Donepezil Hydrochloride	Eisai	Pre-clinical	26